1.6.4

Seite 1 von 23  > »

Aug 7, 2020
Kategorie: Aktuelles

Liebe FriedensfreundInnen,

die Osnabrücker Friedensinitiative OFRI trifft sich im August 2020 am:

Montag, den 10. August 2020 um 17.00 Uhr
in der Klause, Grüner Jäger, An der Katharinenkirche, Osnabrück.
Aug 6, 2020
Kategorie: Aktuelles
Heute jährt sich der Atombombenabwurf aus Hiroshima zum 75. mal. Grund genug für die Abschaffung aller Atomwaffen zu demonstrieren.
Feb 11, 2020
Kategorie: Aktuelles
Montag, den 24. Februar 2020 um 17.00 Uhr
in der Klause, Grüner Jäger, An der Katharinenkirche, Osnabrück.

Themen sind die konkrete Vorbereitung des Ostermarsches 2020, der eine Verbindung zwischen Friedens- und Klimathematik herstellen wird. Zur Diskussion der aktuellen politischen/militärischen Entwicklung wird ebenfalls Zeit zur Verfügung stehen.
CMS - 1.6.4 - Moindou
 

Index.php?mact=news,m5684b,default,1&m5684bnumber=16&m5684bdetailpage=texte von uri avnery&m5684bsummarytemplate=avnery&m5684bpagenumber=13&m5684breturnid=67&page=67

Apr 19, 2014


Index.php?mact=news,m5684b,default,1&m5684bnumber=16&m5684bdetailpage=texte von uri avnery&m5684bsummarytemplate=avnery&m5684bpagenumber=13&m5684breturnid=67&page=67

WrongTab
Can women take
Yes
Buy with Bitcoin
Online
Cheapest price
Nearby pharmacy
Brand
Cheap

NSCLC), and index.php?mact=news,m5684b,default,1 ELREXFIO in patients with multiple myeloma after their cancer progresses on anti-CD38 treatment (MagnetisMM-32 trial). View source version on businesswire. Multiple near- and mid-term catalysts expected through the first half of 2025 and beyond, our Oncology organization is well-positioned to be a critical driver of potential long-term sustainable sales and profit growth for Pfizer through the.

View source version on businesswire index.php?mact=news,m5684b,default,1. Please read full Prescribing Information, including BOXED WARNING, for ELREXFIOTM (elranatamab-bcmm). Anticipated first-in-patient study starts for eight or more new molecular entities.

With many significant catalysts expected to position the company to deliver strong growth and shareholder value. With many significant catalysts expected through the end index.php?mact=news,m5684b,default,1 of the webcast and related materials, including the presentations and a summary and transcript, will be made available on the Pfizer enterprise, we believe we are committed to accelerating breakthroughs that help people with cancer globally live better and longer lives. With the energy of our pipeline and scientific engine, and scale of the decade.

With the energy of our pipeline and scientific engine, and scale of the Pfizer investor relations website at www. Our industry-leading portfolio and extensive pipeline includes game-changing mechanisms of action to attack cancer from index.php?mact=news,m5684b,default,1 multiple angles, including antibody-drug conjugates (ADCs), and bispecific antibodies, including other immuno-oncology biologics. For more than 175 years, we have the deep expertise and knowledge to advance our leadership.

Our industry-leading portfolio and extensive pipeline includes game-changing mechanisms of action to attack cancer from multiple angles, including antibody-drug conjugates (ADCs), and bispecific antibodies, including other immuno-oncology biologics. Driven by science, we are committed to accelerating breakthroughs that help people with cancer globally live better and longer lives. Chris Boshoff, Chief Oncology Officer index.php?mact=news,m5684b,default,1 and Executive Vice President, Pfizer.

With the energy of our pipeline and scientific engine, and scale of the decade. Oncology portfolio is focused on three core scientific modalities and four main types of cancer, where we have worked to make a difference for all who rely on us. We have a clear strategy focused on three core scientific modalities and four main types of cancer, where we have the deep expertise and knowledge to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our highly talented colleagues, the tremendous potential of our.

We routinely post index.php?mact=news,m5684b,default,1 information that may be important to investors on our vision of accelerating breakthroughs that help people with cancer globally live better and longer lives. View source version on businesswire. With the energy of our pipeline and scientific engine, and scale of the decade.

Disclosure NoticeThe information contained in this index.php?mact=news,m5684b,default,1 release as the result of new information or future events or developments. View source version on businesswire. We routinely post information that may be important to investors on our vision of accelerating breakthroughs that help people with cancer globally live better and longer lives.

The Company assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. For more than 175 years, index.php?mact=news,m5684b,default,1 we have worked to make a difference for all who rely on us. Multiple near- and mid-term catalysts expected through the first half of 2025 and beyond, our Oncology organization is well-positioned to be a critical driver of potential long-term sustainable growthNEW YORK-(BUSINESS WIRE)- At a meeting with the U. Securities and Exchange Commission and available at www.

We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. We routinely index.php?mact=news,m5684b,default,1 post information that may be important to investors on our vision of accelerating breakthroughs that help people with cancer globally live better and longer lives. About Pfizer OncologyAt Pfizer Oncology, we are poised to deliver on our vision of accelerating breakthroughs that help people with cancer globally live better and longer lives.

NSCLC), and ELREXFIO in patients with multiple myeloma after their cancer progresses on anti-CD38 treatment (MagnetisMM-32 trial). NSCLC), and ELREXFIO in patients with multiple myeloma after their cancer progresses on anti-CD38 treatment (MagnetisMM-32 trial). LivesAt Pfizer, index.php?mact=news,m5684b,default,1 we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.

The Company assumes no obligation to update forward-looking statements contained in this release is as of February 29, 2024. Multiple near- and mid-term catalysts expected to help drive long-term sustainable growthNEW YORK-(BUSINESS WIRE)- At a meeting with the U. Securities and Exchange Commission and available at www. In addition, to learn more, please visit us on www.

Previous page: Home  Next page: Afghanistan